ESTRO 2024 - Abstract Book

S5681

RTT - Patient experience and quality of life

ESTRO 2024

Lisa Durrant 1 , Alexandra Board 2 , Samantha Bostock 3 , Michele Chirossel 1 , Hazel Clarke 4 , Emma Crozier 5 , David Cullum 6 , Vicki Ferguson 7 , Vicki Hands 1 , Hill Suzanne 8 , Walker Zoe 9 1 Somerset NHS Foundation Trust, Radiotherapy, Taunton, United Kingdom. 2 Royal Devon University Healthcare NHS Foundation Trust, Radiotherapy, Exeter, United Kingdom. 3 Gloucester Hospitals NHS Foundation Trust, Radiotherapy, Cheltenham, United Kingdom. 4 Royal United Hospitals Bath NHS Foundation Trust, Radiotherapy, Bath, United Kingdom. 5 Royal Cornwall Hospitals NHS Trust, Radiotherapy, Truro, United Kingdom. 6 NHS South, Central and West Commissioning Support Unit, Strategy and Transformation, Bristol, United Kingdom. 7 NHS South, Central and West Commissioning Support Unit, Cancer Program, Bristol, United Kingdom. 8 Torbay and South Devon NHS Foundation Trust, Radiotherapy, Torquay, United Kingdom. 9 University Hospitals Bristol and Weston NHS Foundation Trust, Radiotherapy, Bristol, United Kingdom Late effects (LE) of radiotherapy (RT) can be life long, life changing and life limiting. Data to evaluate RT LE are limited, masking the scale and burden of the problem. Post-treatment effects are usually reported as clinician graded toxicities, published many years after primary endpoint data [1]. Quality of life (QoL) data gives a patient perspective to benchmark commissioning, inform health economics and development guidelines [2]. Although radiotherapy has been a mainstay of cancer treatment for decades, its impact on people’s lives has been poorly understood due to a lack of standardisation in QoL reporting. To address this, the UK NHS Cancer QoL Survey was launched in 2020, first reported in October 2021 and updated bi-annually. Data collected using EQ-5D-5L and EORTC QLQ-C30 Patient Reported Outcome Measures (PROMs) are available as a publicly accessible online dashboard searchable by geographical area, cancer type etc. [3]. Questionnaires are currently only offered 18 months after cancer diagnosis, not reflecting the QoL of those with enduring LE which can develop and persist many years after treatment. Data gathered from the novel UK South West Radiotherapy Late Effects Services (SWRLES) [4] using identical PROMs was used to see if useful comparisons could be drawn, to evidence how LE impact QoL. Purpose/Objective:

Material/Methods:

EQ-5D-5L and EORTC QLQ-C30 questionnaires were used under licence. EQ-5D-5L, a non-cancer specific PROM evaluates QoL and five aspects of health: mobility, self-care, usual activities, pain, anxiety/depression [5]. EORTC QLQ-C30, a cancer-specific PROM, incorporates functional scales, symptom scores and QoL [6].

All patients referred to SWRLES completed paper questionnaires collated by a central team and analysed according to the questionnaire scoring manuals and NHS QoL survey information.

Self-reported QoL scales, functional scores, symptom scores and combined scores (functions and symptoms) were compared with NHS Cancer QoL results available from 23/9/23 for 146,000 people from England with a cancer diagnosis (NHS all-cancers), a subset of 9990 people from (Somerset, Wiltshire, Avon, Gloucester Cancer Alliance - SWAG) where SWRLES was established, and where possible normative data of UK people without cancer (UK no cancer).

Results: